scholarly journals 1079. Development of Tebipenem MIC Antimicrobial Susceptibility Test for Gram-negative Bacteria on MicroScan Dried Gram-negative MIC Panels

2021 ◽  
Vol 8 (Supplement_1) ◽  
pp. S631-S631
Author(s):  
Jose Enrique Fernandez ◽  
Robert L Williams ◽  
Vasna Carr ◽  
Renae Miller
Keyword(s):  
Antimicrobial Susceptibility ◽  
The United States ◽  
Susceptibility Test ◽  
Reference Panel ◽  
Gram Negative Bacteria ◽  
Broth Microdilution ◽  
Antimicrobial Susceptibility Test ◽  
Gram Negative ◽  
Registered Trademark ◽  
Development Data

Abstract Background Development of a tebipenem antimicrobial susceptibility test was completed for the MicroScan Dried Gram-negative MIC (MSDGN) Panel when compared to CLSI broth microdilution reference panels. Methods Development was conducted by comparing MICs obtained using the MSDGN panel to MICs using a CLSI broth microdilution reference panel. A total of 669 Enterobacterales isolates were tested at 16, 18, and 20 hour incubation times using the turbidity and Prompt®* methods of inoculation. MSDGN panels were incubated at 35 ± 2ºC and read on the WalkAway System, the autoSCAN-4 instrument, and read visually. Frozen reference panels, prepared according to ISO/CLSI methodology, were inoculated using the turbidity inoculation method. All frozen reference panels were incubated at 35 ± 2ºC and read visually. Dilution sequence evaluated is 0.03-32 µg/mL. Results When compared to frozen reference panel results, essential agreement for all isolates tested during development are as follows: Conclusion The development data showed that tebipenem MIC results for Enterobacterales obtained with the MSDGN panel correlate well with MICs obtained using frozen reference panels. Essential agreement is > 90% for all inoculation and read methods. For Investigational Use Only. The performance characteristics of this product have not been established. * Prompt® is a registered trademark of 3M Company, St. Paul, MN USA. © 2021 Beckman Coulter. All rights reserved. Beckman Coulter, the stylized logo, and the Beckman Coulter product and service marks mentioned herein are trademarks or registered trademarks of Beckman Coulter, Inc. in the United States and other countries. Disclosures Jose Enrique Fernandez, n/a, Beckman Coulter (Employee) Vasna Carr, n/a, Beckman Coulter (Employee) Renae Miller, n/a, Beckman Coulter (Employee)

scholarly journals 2131. Multicenter Evaluation of Meropenem/Vaborbactam MIC Results for Enterobacteriaceae Using MicroScan Dried Gram-Negative MIC Panels

2019 ◽  
Vol 6 (Supplement_2) ◽  
pp. S722-S722
Author(s):  
Omai Garner ◽  
Maria M Traczewski ◽  
Denise Beasley ◽  
Amanda Harrington ◽  
Sharon DesJarlais ◽  
...  
Keyword(s):  
United States ◽  
Multicenter Study ◽  
The United States ◽  
Reference Panel ◽  
Clinical Isolates ◽  
Broth Microdilution ◽  
Gram Negative ◽  
Registered Trademark ◽  
Inoculation Methods ◽  
Inoculation Method

Abstract Background A multicenter study was performed to evaluate the accuracy of meropenem/vaborbactam on a MicroScan Dried Gram-negative MIC (MSDGN) Panel when compared with a frozen CLSI broth microdilution reference panel. Methods For efficacy, an evaluation was conducted at three US sites by comparing MIC values obtained using the MSDGN to MICs using a CLSI broth microdilution reference panel. A total of 560 Enterobacteriaceae clinical isolates were tested using the turbidity and Prompt®* methods of inoculation. For challenge, 95 Enterobacteriaceae isolates were tested on MSDGN panels at one site. For reproducibility, a subset of 14 organisms was tested on MSDGN panels at each site. MSDGN panels were incubated at 35 ± 2°C and read on the WalkAway System, the autoSCAN-4 instrument, and read visually. Read times for the MSDGN panels were at 16–20 hours. Frozen reference panels, prepared according to CLSI/ISO methodology, were inoculated using the turbidity inoculation method. All frozen reference panels were incubated at 35 ± 2°C and read visually. Frozen reference panels were read at 16–20 hours. FDA/CLSI breakpoints (µg/ml) used for interpretation of MIC results were: Enterobacteriaceae ≤ 4/8 S, 8/8 I, and ≥ 16/8 R. Results When compared with frozen reference panel results, essential and categorical agreements for isolates tested in the Efficacy and Challenge are as follows (see table). Reproducibility among the three sites were greater than 95% for all read methods for both the turbidity and Prompt* inoculation methods. Conclusion This multicenter study showed that meropenem/vaborbactam MIC results for Enterobacteriaceae obtained with the MSDGN panel correlate well with MICs obtained using frozen reference panels using FDA/CLSI interpretive criteria. * PROMPT® is a registered trademark of 3M Company, St. Paul, MN, USA. Beckman Coulter, the stylized logo and the Beckman Coulter product and service marks mentioned herein are trademarks or registered trademarks of Beckman Coulter, Inc. in the United States and other countries. Vabomere® (Meropenem/Vaborbactam) is a registered trademark of Melinta Therapeutics, Inc. Disclosures All authors: No reported disclosures.

scholarly journals 2132. Multicenter Evaluation of Eravacycline MIC Results for Enterobacteriaceae Using MicroScan Dried Gram-Negative MIC Panels

2019 ◽  
Vol 6 (Supplement_2) ◽  
pp. S722-S722
Author(s):  
Maria M Traczewski ◽  
Denise Beasley ◽  
Amanda Harrington ◽  
Sharon DesJarlais ◽  
Omai Garner ◽  
...  
Keyword(s):  
United States ◽  
Multicenter Study ◽  
The United States ◽  
Reference Panel ◽  
Clinical Isolates ◽  
Broth Microdilution ◽  
Gram Negative ◽  
Registered Trademark ◽  
Inoculation Methods ◽  
Inoculation Method

Abstract Background A multicenter study was performed to evaluate the accuracy of eravacycline on a MicroScan Dried Gram-negative MIC (MSDGN) Panel when compared with a frozen CLSI broth microdilution reference panel. Methods For efficacy, an evaluation was conducted at three sites by comparing MIC values obtained using the MSDGN to MICs using a CLSI broth microdilution reference panel. A total of 414 Enterobacteriaceae clinical isolates were tested using the turbidity and Prompt®* methods of inoculation. For challenge, 79 Enterobacteriaceae isolates were tested on MSDGN panels at one site. For reproducibility, a subset of 11 organisms was tested on MSDGN panels at each site. MSDGN panels were incubated at 35 ± 2°C and read on the WalkAway System, the autoSCAN-4 instrument, and read visually. Read times for the MSDGN panels were at 16–20 hours. Frozen reference panels, prepared according to CLSI/ISO methodology, were inoculated using the turbidity inoculation method. All frozen reference panels were incubated at 35 ± 2°C and read visually. Frozen reference panels were read at 16–20 hours. FDA breakpoints (µg/mL) used for interpretation of MIC results were: Enterobacteriaceae ≤ 0.5 S. Potential major and very major errors were calculated using the NS result in place of resistant (R). Results When compared with frozen reference panel results, essential and categorical agreements for isolates tested in the Efficacy and Challenge are as follows (see table). Reproducibility among the three sites were greater than 95% for all read methods for both the turbidity and Prompt inoculation methods. Conclusion This multicenter study showed that eravacycline MIC results for Enterobacteriaceae obtained with the MSDGN panel correlate well with MICs obtained using frozen reference panels using FDA interpretive criteria. * PROMPT® is a registered trademark of 3M Company, St. Paul, MN USA. Beckman Coulter, the stylized logo and the Beckman Coulter product and service marks mentioned herein are trademarks or registered trademarks of Beckman Coulter, Inc. in the United States and other countries. Xerava™ (Eravacycline) is a registered trademark of Tetraphase Pharmaceuticals, Inc. Disclosures All authors: No reported disclosures.

scholarly journals Chryseobacterium indologenes as a Rare Pathogen of Bacteremia in Febrile Neutropenia

2021 ◽  
Author(s):  
Begümhan Demir Gündoğan ◽  
Fatih Sağcan ◽  
Elvan Çağlar Çıtak
Keyword(s):  
Risk Factors ◽  
Febrile Neutropenia ◽  
Broad Spectrum ◽  
Antimicrobial Susceptibility ◽  
Neutropenic Fever ◽  
Susceptibility Test ◽  
Antimicrobial Susceptibility Test ◽  
Gram Negative ◽  
Chryseobacterium Indologenes ◽  
Test Result

Chryseobacterium indologenes (C. indologenes) is nonmotile, oxidase-, and indole-positive gram-negative aerobic bacillus. Immunosuppression, comorbidities, use of broad-spectrum antibiotics are known risk factors for C. indologenes-related infections. We report a neutropenic fever caused by C. indologenes in a 16-month-old boy who was treated due to the neuroblastoma. According to the antimicrobial susceptibility test result, he was treated with cephaperazone/sulbactam.

scholarly journals Antimicrobial susceptibility pattern of carbapenemase-producing Gram-negative nosocomial bacteria at Al Zahra hospital, Isfahan, Iran

2021 ◽  
Author(s):  
Sima Bahrami ◽  
Fatemeh Shafiee ◽  
Atousa Hakamifard ◽  
Hossein Fazeli ◽  
Rasool Soltani
Keyword(s):  
Antimicrobial Susceptibility ◽  
Nosocomial Infections ◽  
Susceptibility Test ◽  
High Rate ◽  
Diffusion Method ◽  
Gram Negative Bacteria ◽  
Susceptibility Pattern ◽  
Gram Negative ◽  
Antimicrobial Susceptibility Pattern ◽  
Vitro Effect

Background and Objectives: Bacterial antibiotic resistance is one of the most important threats for public health around the world. Carbapenemase-producing Gram-negative bacteria have resistance to most antibiotics including carbapenems complicating the treatment of infections. The aim of this study was to determine the antimicrobial susceptibility pattern of carbapenemase-producing nosocomial Gram-negative pathogens at a referral teaching hospital to reveal the best options for treatment of related infections. Materials and Methods: Gram-negative bacteria, isolated from hospitalized patients with nosocomial infections, underwent meropenem susceptibility test by disk diffusion method. Meropenem-resistant strains were evaluated for the presence of carbapenemase using Modified Hodge test (MHT). Finally, the antibiotic susceptibility test was performed to determine the sensitivity of each carbapenemase-positive strain against various antimicrobial agents according to the guidelines of Clinical and Laboratory Standards Institute (CLSI). Results: Over the study period, 155 carbapenemase-positive isolates were detected. Pneumonia was the most frequent related nosocomial infection (67.1%) followed by UTI (23.2%). Acinetobacter baumannii (53.5%) and Klebsiella pneumoniae (40%) were the most frequently isolated pathogens. The pathogens had high rate of resistance to all antibiotics. Colistin had the most in vitro effect against all pathogens. Also, K. pneumoniae had a co-trimoxazole sensitivity rate equal to colistin (30.6%). Conclusion: Carbapenemase-positive Gram-negative bacteria causing nosocomial infections are common in our hospital and have high rate of resistance to most antibiotics. Improvement in the pattern of antibiotic use and infection control measures are necessary to overcome this resistance.

scholarly journals A fast impedance-based antimicrobial susceptibility test

2020 ◽  
Vol 11 (1) ◽  
Author(s):  
Daniel C. Spencer ◽  
Teagan F. Paton ◽  
Kieran T. Mulroney ◽  
Timothy J. J. Inglis ◽  
J. Mark Sutton ◽  
...  
Keyword(s):  
Antimicrobial Susceptibility ◽  
Mode Of Action ◽  
Bacterial Species ◽  
Susceptibility Test ◽  
Electrical Characteristics ◽  
Label Free ◽  
Broth Microdilution ◽  
Antimicrobial Susceptibility Test ◽  
Antimicrobial Susceptibility Tests ◽  
Susceptibility Tests

Abstract There is an urgent need to develop simple and fast antimicrobial susceptibility tests (ASTs) that allow informed prescribing of antibiotics. Here, we describe a label-free AST that can deliver results within an hour, using an actively dividing culture as starting material. The bacteria are incubated in the presence of an antibiotic for 30 min, and then approximately 105 cells are analysed one-by-one with microfluidic impedance cytometry for 2–3 min. The measured electrical characteristics reflect the phenotypic response of the bacteria to the mode of action of a particular antibiotic, in a 30-minute incubation window. The results are consistent with those obtained by classical broth microdilution assays for a range of antibiotics and bacterial species.

Sign in / Sign up

Export Citation Format

Share Document